RBC Capital Downgrades Immunogen Inc. (IMGN) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to RBC Capital Downgrades Immunogen Inc. (IMGN) to Sector Perform
May 2, 2016 9:49 AM EDT
Morgan Stanley maintained an Underweight rating on Immunogen Inc. (NASDAQ: IMGN) and lowered its price target to $5.00 (from $9.00).
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $6.85 yesterday.
...
More
April 29, 2016 2:28 PM EDT
(Updated - April 29, 2016 2:44 PM EDT)
RBC Capital downgraded Immunogen Inc. (NASDAQ: IMGN) from Outperform to Sector Perform with a price target of $7.00 (from $18.00). Analyst Simos Simeonidis didn't like what he heard on the company's conference call regarding lead asset mirvetuximab soravtansine.
"We are downgrading IMGN to Sector Perform (from Outperform) on the news that lead asset mirvetuximab soravtansine produced a... More
April 29, 2016 8:33 AM EDT
Immunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.37), $0.05 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $23.02 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
...
More
